Biotin Rabbit anti-Human CD45RA Monoclonal Antibody for Flow Cytometry - P08575-8

Core Product Specifications and Parameters

Biological Background: CD45RA Function and Localization

• The target protein is Isoform 6 of Receptor-type tyrosine-protein phosphatase C (UniProt: P08575-8), commonly referred to as CD45RA.
• It is a specific splice variant of the PTPRC gene (CD45), which gives rise to multiple isoforms through alternative splicing.
• Alternative names for this protein include Leukocyte common antigen (L-CA) and T200, reflecting its abundant expression on white blood cells.
• The molecular weight of this isoform is approximately 138,034 Da (reported as 138 kDa).
• As a receptor-type tyrosine-protein phosphatase, CD45RA is predicted to span the membrane and play a key role in regulating cellular signaling through dephosphorylation.
• The designation "leukocyte common antigen" underscores its broad expression in various leukocyte populations.

Experimental Guidance and Technical Tips

• This biotinylated monoclonal antibody is intended for flow cytometry (FC) detection of human CD45RA.
• Consider titrating the antibody to determine the optimal working dilution for your specific cell type and experimental conditions.
• For signal detection, use a streptavidin conjugate compatible with your flow cytometry setup; ensure the fluorophore matches your instrument’s lasers and filters.
• As CD45RA is a cell surface antigen, live cell staining without permeabilization is typically suitable; include appropriate isotype controls to assess specificity.
• Protect the antibody from light during handling and storage to maintain biotin activity and reagent stability.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio offers a comprehensive one-stop platform for IVD raw-material procurement, from research-grade reagents to bulk production needs. This anti-CD45RA monoclonal antibody is part of our portfolio supporting immunology research and diagnostic assay development. We can assist with validated antibody pairs, optimized monoclonal and polyclonal antibodies, ancillary reagents, and rare target sourcing—bridging your concept to clinic seamlessly.